For US Healthcare Professionals

Sotalol IV Logo


Listen in on conversations about Sotalol IV, antiarrhythmics, & other electrophysiology topics. Hosted by Dr. Eva Nelson, AltaThera Director Education & Training.

Podcast 02 - An Overview of the Sotalol IV PEAKS Registry

[Podcast] An Overview of the Sotalol IV PEAKS Registry

We continue our conversation with T. Jared Bunch, MD, focusing on the Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS) Registry. Bunch highlights the value the new data has in understanding typical IV Sotalol patients, evaluating practice patterns across the country, and the impact the registry alongside existing modeling data has on the future of diagnosing arrhythmias.

Listen »

If you received a password from a member of AltaThera’s Clinical or Education team, enter it below. 

Highlights of Prescribing Information

Boxed Warning, Indications, and Important Safety Information


Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation. To minimize the risk of drug induced arrhythmia, initiate or uptitrate intravenous sotalol in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)].
Do not initiate intravenous sotalol therapy if the baseline QTc is longer than 450 ms. If the QTc prolongs to 500 ms or greater, reduce the dose or discontinue. (2.3)